Investors
Healthcare Professionals
Newsroom
Clinical Trials
English
German
Connect
About
About
Who We Are
Vision & Mission
History
Our Board Members
Our Senior Team
Collaborators
Sites & Subsidiaries
Our Responsibility
Corporate Social Responsibility
Global Health
Research & Innovation
Research & Innovation
Our Approach
Therapeutic Areas
Drug Classes
Overview
mRNA
Engineered Cell Therapies
Protein-based Therapeutics
Small Molecule Immunomodulators
Scientific Publications
Pipeline & Products
Pipeline & Products
Pipeline
Platforms
Our Platforms
mRNA Platforms
Cell Therapy Platforms
Protein-based Platforms
Small Molecule Platforms
Clinical Trials
Manufacturing & Services
Manufacturing & Services
Production Network
Careers
Careers
Career at BioNTech
Entry Level Roles
Offer for Professionals
Investors
Healthcare Professionals
Newsroom
Clinical Trials
See our Annual Report for the year 2024 for detailed updates on our pipeline candidates.
Annual Report 2024
Annual Report 2024
Pipeline
Breakthrough technologies to revolutionize medicine
Download PDF summary
Home
Pipeline & Products
Pipeline
2
pan-tumor priority programs
Explore our priority programs
20+
phase 2 and phase 3 clinical trials in oncology
Explore mid- to late-stage clinical trials
€2.25
bn
investment into R&D in 2024
Explore our diversified pipeline
Stay up to date
Sign up for our email alert for news on our growing pipeline
Sign up now
